Anti-CD40 Monoclonal Antibody Clinical Trial

A Phase 1, Open-label, Dose-escalation Trial of Anti-CD40 Monoclonal Antibody (CHIR-12.12) Administered Intravenously to Subjects With Advanced Multiple Myeloma that is Refractory or Relapsed After Prior Treatment

The primary objective is to determine the safety, pharmacokinetics, and pharmacodynamics of CHIR-12.12 administered intravenously (IV) at escalating multiple doses to subjects with multiple myeloma (MM) that is relapsed or refractory after prior treatment.

The secondary objective is to report the clinical response after various doses of IV CHIR 12.12 in subjects with MM that is refractory or relapsed after prior treatment.

Seattle, WA, Fred Hutchinson Cancer Center
PI: Dr. William Bensinger, Kathy Lilleby, 206-667-5836, klilleby@fhcrc.org